• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型荧光黄嘌呤衍生物作为蛋白激酶抑制剂的研究进展

Development of new fluorescent xanthines as kinase inhibitors.

机构信息

Department of Chemistry, Korea Advanced Institute of Science and Technology, Daejeon, 305-701, Korea.

出版信息

Org Lett. 2010 Mar 19;12(6):1212-5. doi: 10.1021/ol100011n.

DOI:10.1021/ol100011n
PMID:20184370
Abstract

An efficient and versatile synthetic approach for the preparation of highly substituted xanthine derivatives has been developed by a combination of direct N7- and C8-arylation. With this method, diverse xanthine analogues were prepared and potent kinase inhibitors could be identified. For example, compound 8a inhibits PI3Ks and proliferation in T47D tumor cells. In addition, these xanthine-based kinase inhibitors exhibited significant fluorescence emission in a concentration-dependent response.

摘要

已开发出一种高效、通用的合成方法,通过直接 N7-和 C8-芳基化组合制备高度取代的黄嘌呤衍生物。使用该方法,制备了多种黄嘌呤类似物,并鉴定出有效的激酶抑制剂。例如,化合物 8a 抑制 T47D 肿瘤细胞中的 PI3Ks 和增殖。此外,这些基于黄嘌呤的激酶抑制剂在浓度依赖性响应中表现出显著的荧光发射。

相似文献

1
Development of new fluorescent xanthines as kinase inhibitors.新型荧光黄嘌呤衍生物作为蛋白激酶抑制剂的研究进展
Org Lett. 2010 Mar 19;12(6):1212-5. doi: 10.1021/ol100011n.
2
Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.新型7-氮杂吲唑基-吲哚基-马来酰亚胺衍生物作为抗肿瘤剂和蛋白激酶C抑制剂的合成与评价
Bioorg Med Chem. 2009 Jul 1;17(13):4763-72. doi: 10.1016/j.bmc.2009.04.043. Epub 2009 May 3.
3
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.新型哌嗪基嘧啶衍生物的发现、合成及抗肿瘤活性研究。
Eur J Med Chem. 2011 Jun;46(6):2043-57. doi: 10.1016/j.ejmech.2011.02.057. Epub 2011 Mar 3.
4
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.鉴定和优化新型、选择性小分子 mTOR 激酶抑制剂。
Bioorg Med Chem Lett. 2009 Oct 15;19(20):5898-901. doi: 10.1016/j.bmcl.2009.08.069. Epub 2009 Aug 21.
5
Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.合成、分子对接及噻唑基-吡唑啉衍生物作为 EGFR TK 抑制剂和潜在抗癌剂的评价。
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5374-7. doi: 10.1016/j.bmcl.2011.07.010. Epub 2011 Jul 14.
6
Synthesis, kinase inhibitory potencies and in vitro antiproliferative activity of isoindigo and 7'-azaisoindigo derivatives substituted by Sonogashira cross-coupling.通过Sonogashira交叉偶联取代的异吲哚并二酮和7'-氮杂异吲哚并二酮衍生物的合成、激酶抑制活性及体外抗增殖活性
Eur J Med Chem. 2009 Jun;44(6):2705-10. doi: 10.1016/j.ejmech.2009.01.027. Epub 2009 Feb 5.
7
N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.N-(4-(6,7-二取代喹啉-4-基氧基)-3-氟苯基)-2-氧代-3-苯基咪唑烷-1-甲酰胺:新型双c-Met/VEGFR2受体酪氨酸激酶抑制剂系列
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6552-6. doi: 10.1016/j.bmcl.2009.10.040. Epub 2009 Oct 13.
8
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.萘酰胺类化合物作为新型强效血管内皮生长因子受体酪氨酸激酶抑制剂:设计、合成与评价
J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.
9
Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.设计、合成并评价噻唑烷酮衍生物作为潜在的表皮生长因子受体(EGFR)和人表皮生长因子受体-2(HER-2)激酶抑制剂。
Bioorg Med Chem. 2010 Jan 1;18(1):314-9. doi: 10.1016/j.bmc.2009.10.051. Epub 2009 Oct 30.
10
Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.酰胺偶联苯甲氮芥衍生物的合成、生物评价及分子对接研究作为潜在的抗肿瘤剂。
Bioorg Med Chem. 2010 Jan 15;18(2):880-6. doi: 10.1016/j.bmc.2009.11.037. Epub 2009 Nov 22.

引用本文的文献

1
Geminal-atom catalysis for cross-coupling.偕二原子催化交叉偶联反应。
Nature. 2023 Oct;622(7984):754-760. doi: 10.1038/s41586-023-06529-z. Epub 2023 Sep 20.
2
Fluorescent kinase inhibitors as probes in cancer.荧光激酶抑制剂作为癌症研究中的探针
Chem Soc Rev. 2021 Sep 7;50(17):9794-9816. doi: 10.1039/d1cs00017a. Epub 2021 Jul 22.
3
A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding.一种荧光激酶抑制剂,在结合后会在发射光谱上显示出诊断变化。
Angew Chem Int Ed Engl. 2019 Oct 14;58(42):15000-15004. doi: 10.1002/anie.201909536. Epub 2019 Sep 5.
4
Xanthine scaffold: scope and potential in drug development.黄嘌呤骨架:药物研发中的范围与潜力
Heliyon. 2018 Oct 3;4(10):e00829. doi: 10.1016/j.heliyon.2018.e00829. eCollection 2018 Oct.
5
Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.作为抗癌药物的ATP竞争性小分子磷脂酰肌醇-3-激酶抑制剂的最新进展。
Oncotarget. 2017 Jan 24;8(4):7181-7200. doi: 10.18632/oncotarget.12742.
6
HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy.HS-133,一种新型荧光磷脂酰肌醇3-激酶抑制剂,作为靶向治疗的潜在成像和抗癌药物。
Oncotarget. 2014 Oct 30;5(20):10180-97. doi: 10.18632/oncotarget.2507.
7
Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.一种近红外荧光碳菁对胆碱激酶的直接抑制作用。
Mol Cancer Ther. 2014 Sep;13(9):2149-58. doi: 10.1158/1535-7163.MCT-14-0085. Epub 2014 Jul 15.
8
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.I 类和 I/IV 双磷酸肌醇 3-激酶 (PI3K) 抑制剂的临床前发现和临床开发进展。
Curr Med Chem. 2011;18(18):2686-714. doi: 10.2174/092986711796011229.
9
Palladium- and copper-mediated N-aryl bond formation reactions for the synthesis of biological active compounds.钯和铜介导的 N-芳基键形成反应在生物活性化合物的合成中的应用。
Beilstein J Org Chem. 2011 Jan 14;7:59-74. doi: 10.3762/bjoc.7.10.